Center for Biotechnology and Genomic Medicine, Medical College of Georgia, Augusta, Georgia, United States of America.
PLoS One. 2010 Oct 26;5(10):e13623. doi: 10.1371/journal.pone.0013623.
The presence of Foxp3(+) regulatory CD4(+) T cells in tumor lesions is considered one of the major causes of ineffective immune response in cancer. It is not clear whether intratumoral T(reg) cells represent T(reg) cells pre-existing in healthy mice, or arise from tumor-specific effector CD4(+) T cells and thus representing adaptive T(reg) cells. The generation of T(reg) population in tumors could be further complicated by recent evidence showing that both in humans and mice the peripheral population of T(reg) cells is heterogenous and consists of subsets which may differentially respond to tumor-derived antigens. We have studied T(reg) cells in cancer in experimental mice that express naturally selected, polyclonal repertoire of CD4(+) T cells and which preserve the heterogeneity of the T(reg) population. The majority of T(reg) cells present in healthy mice maintained a stable suppressor phenotype, expressed high level of Foxp3 and an exclusive set of TCRs not used by naive CD4(+) T cells. A small T(reg) subset, utilized TCRs shared with effector T cells and expressed a lower level of Foxp3. We show that response to tumor-derived antigens induced efficient clonal recruitment and expansion of antigen-specific effector and T(reg) cells. However, the population of T(reg) cells in tumors was dominated by cells expressing TCRs shared with effector CD4(+) T cells. In contrast, T(reg) cells expressing an exclusive set of TCRs, that dominate in healthy mice, accounted for only a small fraction of all T(reg) cells in tumor lesions. Our results suggest that the T(reg) repertoire in tumors is generated by conversion of effector CD4(+) T cells or expansion of a minor subset of T(reg) cells. In conclusion, successful cancer immunotherapy may depend on the ability to block upregulation of Foxp3 in effector CD4(+) T cells and/or selectively inhibiting the expansion of a minor T(reg) subset.
Foxp3(+) 调节性 CD4(+) T 细胞存在于肿瘤病灶中,被认为是癌症中免疫反应无效的主要原因之一。目前尚不清楚肿瘤内的 T(reg)细胞是预先存在于健康小鼠中的 T(reg)细胞,还是来自肿瘤特异性效应 CD4(+) T 细胞,并因此代表适应性 T(reg)细胞。肿瘤中 T(reg)细胞群体的产生可能会更加复杂,因为最近的证据表明,在人类和小鼠中,外周 T(reg)细胞群体是异质的,由可能对肿瘤衍生抗原产生不同反应的亚群组成。我们在表达天然选择的、多克隆 CD4(+) T 细胞 repertoire 的实验小鼠中研究了癌症中的 T(reg)细胞,并保留了 T(reg)细胞群体的异质性。在健康小鼠中存在的大多数 T(reg)细胞保持稳定的抑制表型,表达高水平的 Foxp3 和一组独特的 TCR,这些 TCR 不被幼稚 CD4(+) T 细胞使用。一小部分 T(reg)细胞亚群利用与效应 T 细胞共享的 TCR,并表达较低水平的 Foxp3。我们表明,对肿瘤衍生抗原的反应诱导了抗原特异性效应和 T(reg)细胞的有效克隆募集和扩增。然而,肿瘤中的 T(reg)细胞群体主要由与效应 CD4(+) T 细胞共享 TCR 的细胞组成。相比之下,在健康小鼠中占主导地位的、表达独特 TCR 的 T(reg)细胞仅占肿瘤病变中所有 T(reg)细胞的一小部分。我们的结果表明,肿瘤中的 T(reg) repertoire 是通过效应 CD4(+) T 细胞的转化或少数 T(reg)细胞亚群的扩增产生的。总之,成功的癌症免疫疗法可能取决于阻断效应 CD4(+) T 细胞中 Foxp3 的上调和/或选择性抑制少数 T(reg)细胞亚群的扩增的能力。